These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 35148573)

  • 21. Population pharmacokinetics of golimumab in patients with ankylosing spondylitis: impact of body weight and immunogenicity.
    Xu ZH; Lee H; Vu T; Hu C; Yan H; Baker D; Hsu B; Pendley C; Wagner C; Davis HM; Zhou H
    Int J Clin Pharmacol Ther; 2010 Sep; 48(9):596-607. PubMed ID: 20860913
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Relative bioavailability, immunogenicity, and safety of two adalimumab-adbm formulations in healthy volunteers: a double-blind, randomized, single-dose, parallel-arm Phase I trial (VOLTAIRE-HCLF).
    Moschetti V; Buschke S; Bertulis J; Hohl K; McCabe D
    Expert Opin Biol Ther; 2024 Jul; 24(7):673-679. PubMed ID: 38739422
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics and safety of CT-P17 (40 mg/0.4 ml) versus reference adalimumab: randomized study in healthy Japanese adults.
    Haranaka M; Tanaka T; Kim S; Bae Y; Jeon D; Choi E; Cha J; Lee S; Ogama Y
    Immunotherapy; 2023 Feb; 15(3):149-161. PubMed ID: 36748363
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Differences in immunogenicity associated with non-product related variability: insights from two pharmacokinetic studies using GP2017, an adalimumab biosimilar.
    von Richter O; Lemke L; Haliduola H; Balfour A; Zehnpfennig B; Skerjanec A; Jauch-Lembach J
    Expert Opin Biol Ther; 2019 Oct; 19(10):1057-1064. PubMed ID: 31002537
    [No Abstract]   [Full Text] [Related]  

  • 25. A randomized phase I comparative pharmacokinetic study comparing SB5 with reference adalimumab in healthy volunteers.
    Shin D; Lee Y; Kim H; Körnicke T; Fuhr R
    J Clin Pharm Ther; 2017 Dec; 42(6):672-678. PubMed ID: 28675520
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A phase 1, randomized, open-label, single-dose study to assess the relative bioavailability of a subcutaneous dose of FKB327 when administered using a prefilled syringe, a prefilled auto-injector, or a vial with disposable syringe in healthy subjects.
    Bush J; Kawakami K; Muniz R
    BMC Pharmacol Toxicol; 2019 Dec; 20(1):87. PubMed ID: 31888742
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Changes in Efficacy Indicators for Adalimumab Biosimilar Candidate (HS016) for the Treatment of Active Ankylosing Spondylitis at Various Time Points.
    Su J; Li M; He L; Zhao D; Wan W; Liu Y; Xu J; Xu J; Liu H; Jiang L; Wu H; Zuo X; Huang C; Liu X; Li F; Zhang Z; Liu X; Dong L; Li T; Chen H; Li J; He D; Lu X; Huang A; Tao Y; Wang Y; Zhang Z; Wei W; Li X; Zeng X
    Front Pharmacol; 2020; 11():606497. PubMed ID: 33364967
    [No Abstract]   [Full Text] [Related]  

  • 28. A Global Phase I Clinical Study Comparing the Safety and Pharmacokinetics of Proposed Biosimilar BAT1706 and Bevacizumab (Avastin
    Wu X; Wynne C; Xu C; Gan Y; Wang C; Thomas BE; Yu JC; Li S; Zhang L
    BioDrugs; 2019 Jun; 33(3):335-342. PubMed ID: 31016568
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A phase I, randomized, double-blinded, single-dose study evaluating the pharmacokinetic equivalence of the biosimilar IBI305 and bevacizumab in healthy male subjects
.
    Zhang H; Zhu X; Wei H; Li C; Chen H; Li X; Wu M; Liu J; Chen G; Zhou H; Zheng S; Ding Y
    Int J Clin Pharmacol Ther; 2019 Mar; 57(3):167-174. PubMed ID: 30663977
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative pharmacokinetics of an adalimumab biosimilar SB5 administered via autoinjector or prefilled syringe in healthy subjects.
    Shin D; Lee Y; Jeong D; Ellis-Pegler R
    Drug Des Devel Ther; 2018; 12():3799-3805. PubMed ID: 30464411
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Randomised, phase I pharmacokinetic study of adalimumab biosimilar CT-P17 (40 mg/0.4 mL) by autoinjector and prefilled syringe in healthy subjects.
    Davidson A; Brimhall D; Kay J; Keystone E; Lee SJ; Kim SH; Bae YJ; Choi EJ; Furst DE
    Br J Clin Pharmacol; 2021 Nov; 87(11):4323-4333. PubMed ID: 33822406
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A randomized, double-blind, parallel-group, single‑dose, pharmacokinetic bioequivalence study of INTP24 and bevacizumab in healthy adult men.
    Singh I; Patel R; Patel A; Jose V
    Cancer Chemother Pharmacol; 2020 Aug; 86(2):193-202. PubMed ID: 32627073
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A randomized, double-blind, parallel-group phase I study comparing the pharmacokinetics, safety, and immunogenicity of LY01008, a candidate bevacizumab biosimilar, with its reference product Avastin® in healthy Chinese male subjects.
    Zhou R; Yang J; Liu Y; Zhang Q; Lu C; Tang K; Li X; Tang W; Gao E; Wu C; Dou C; Hu W
    Expert Opin Biol Ther; 2022 Feb; 22(2):263-269. PubMed ID: 34913787
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Establishing PK Equivalence Between Adalimumab and ABP 501 in the Presence of Antidrug Antibodies Using Population PK Modeling.
    Doshi S; Wang H; Chow V
    Clin Ther; 2022 Jan; 44(1):111-122. PubMed ID: 35123804
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study.
    Weisman MH; Moreland LW; Furst DE; Weinblatt ME; Keystone EC; Paulus HE; Teoh LS; Velagapudi RB; Noertersheuser PA; Granneman GR; Fischkoff SA; Chartash EK
    Clin Ther; 2003 Jun; 25(6):1700-21. PubMed ID: 12860493
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A comparative pharmacokinetic study of DRL_BZ, a candidate biosimilar of bevacizumab, with Avastin
    Wynne C; Schwabe C; Batra SS; Lopez-Lazaro L; Kankanwadi S
    Br J Clin Pharmacol; 2018 Oct; 84(10):2352-2364. PubMed ID: 29943831
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparative assessment of pharmacokinetics, and pharmacodynamics between RTXM83™, a rituximab biosimilar, and rituximab in diffuse large B-cell lymphoma patients: a population PK model approach.
    Candelaria M; Gonzalez D; Fernández Gómez FJ; Paravisini A; Del Campo García A; Pérez L; Miguel-Lillo B; Millán S
    Cancer Chemother Pharmacol; 2018 Mar; 81(3):515-527. PubMed ID: 29362903
    [TBL] [Abstract][Full Text] [Related]  

  • 38. IBI303, a biosimilar to adalimumab, for the treatment of patients with ankylosing spondylitis in China: a randomised, double-blind, phase 3 equivalence trial.
    Xu H; Li Z; Wu J; Xing Q; Shi G; Li J; Liu X; Wu L; Li X; Tan W; He D; Bi L; Li H; Xiao Z; Shuai Z; Li X; Wang Y; Luo L; Zheng Y; Xiao W; Wu X; Zhou L; Li T; Qian L; Zhou H; Lu S; Zheng S; Xiong Y; Wang X; Wang Y; Wu X
    Lancet Rheumatol; 2019 Sep; 1(1):e35-e43. PubMed ID: 38229357
    [TBL] [Abstract][Full Text] [Related]  

  • 39. SB5: An Adalimumab Biosimilar.
    Frampton JE
    BioDrugs; 2018 Oct; 32(5):507-510. PubMed ID: 30251234
    [TBL] [Abstract][Full Text] [Related]  

  • 40. AURIEL-PsO: a randomized, double-blind phase III equivalence trial to demonstrate the clinical similarity of the proposed biosimilar MSB11022 to reference adalimumab in patients with moderate-to-severe chronic plaque-type psoriasis.
    Hercogová J; Papp KA; Chyrok V; Ullmann M; Vlachos P; Edwards CJ
    Br J Dermatol; 2020 Feb; 182(2):316-326. PubMed ID: 31206593
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.